本文へ移動
cccskills
無料GitHub で公開

carelink-interpreter

Systematically interpret a Medtronic CareLink or MiniMed 780G Daily Review download in a structured 6-step clinical workflow — covering Time in Range, insulin delivery, day/night patterns, hypo and hyperglycemia root causes, and a prioritised action plan. Trigger when a clinician uploads or shares a CareLink report, MiniMed download, 780G Daily Review, pump download, or asks to review a patient's CGM or insulin pump data.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md11.0 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

CareLink / MiniMed 780G Report Interpreter

BEFORE YOU BEGIN

When a CareLink file is uploaded, read it carefully. Identify:

  1. Report type — Daily Review (780G/770G) vs classic CareLink (Therapy Management Dashboard, Episode Summary, Sensor & Meter Overview)
  2. Device — MiniMed 780G (SmartGuard Auto Mode = closed-loop), 770G, 640G, or older open-loop pump
  3. Date range — How many days of data?
  4. Units — mg/dL or mmol/L (multiply mmol/L × 18.0182 to convert)

For MiniMed 780G Daily Review: The report shows TDD, Total Basal %, Total Bolus %, food bolus, Auto Correction bolus, and daily glucose traces with Time in Range (TIR) bars on the right. This is the primary format for current closed-loop pump users.


STEP 1 — TIME IN RANGE SCORECARD (Start here. Always.)

Extract from the report:

  • % time in range (70–180 mg/dL / 3.9–10.0 mmol/L)
  • % time above range (>180 mg/dL)
  • % time very high (>250 mg/dL / >13.9 mmol/L)
  • % time below range (<70 mg/dL / <3.9 mmol/L)
  • % time very low (<54 mg/dL / <3.0 mmol/L)

Targets (ADA/International Consensus 2019):

MetricTarget (T1D / insulin-treated T2D)Flag if...
TIR (70–180)≥70%<70% needs action
Time above 180<25%>25% = hyperglycaemia problem
Time above 250<5%>5% = significant problem
Time below 70<4%>4% = hypoglycaemia problem
Time below 54<1%ANY value is urgent

Adjust target to ≥50% TIR for elderly or high-risk patients.

Report findings: State overall TIR, whether targets are met, and on which days control was best vs worst. Note day-to-day variability — consistent vs erratic patterns have different causes.


STEP 2 — INSULIN DELIVERY ANALYSIS

For MiniMed 780G Daily Review, extract per day:

  • TDD (Total Daily Dose in Units)
  • Total Basal % and units
  • Total Bolus % and units → broken into:
    • Food Bolus (user-initiated, meal-related)
    • Auto Correction (SmartGuard-delivered without user input)

Interpret:

TDD trend:

  • Rising TDD over days → insulin needs increasing, or carbohydrate intake rising
  • Falling TDD → improving control, less Auto Correction needed, or reduced eating
  • Marked day-to-day variability → erratic eating or lifestyle variation

Basal/Bolus ratio:

  • Normal in closed-loop: ~30–40% basal, 60–70% bolus
  • Basal >50% → check if SmartGuard is compensating for under-bolusing, or if basal rate is set too high
  • Basal <25% → may suggest frequent manual suspends, or aggressive food bolusing

Auto Correction bolus (780G only):

  • Auto Correction <20% of total bolus → SmartGuard managing minor corrections ✓
  • Auto Correction 20–35% → system working reasonably, watch for patterns
  • Auto Correction >35% → system compensating heavily → likely meal boluses are too small, ICR needs adjustment, or meal timing is off
  • High Auto Correction with still-high TIR → system is coping; if TIR is poor, ICR or basal target needs review

STEP 3 — PATTERN ANALYSIS (Read the glucose traces)

Work through the day in four segments. For each segment note: glucose level, trend direction, and what insulin was active.

Overnight (12AM – 6AM):

  • Flat, in-range trace → basal adequate ✓
  • Rising overnight → basal too low, or dawn phenomenon (common 3–6AM rise)
  • Falling overnight / lows → basal too high, or residual insulin from late correction
  • In Auto Mode (780G): look for auto-basal activity (pink shading). Persistent overnight highs despite active auto-basal → consider raising SmartGuard glucose target

Morning fasting / breakfast period (6AM – 10AM):

  • Glucose at target on waking → overnight basal correct ✓
  • Waking high → overnight basal insufficient OR dawn phenomenon
  • Post-breakfast spike >180 lasting >2 hours → breakfast ICR too low, or bolus given too late
  • Check carb entry vs food bolus: are carbs consistently entered?

Daytime / lunch / afternoon (10AM – 6PM):

  • Post-meal peaks >250 mg/dL → review ICR for that meal period
  • Correction boluses clustering at the same time each day → systematic ICR problem at that meal
  • Bolus overrides (negative correction) → patient is reducing recommended bolus; counsel on trust in Bolus Wizard
  • Delayed site change flag (>3.5 days between cannula fills) → check infusion site as cause of hyperglycaemia

Evening / dinner / overnight transition (6PM – 12AM):

  • Post-dinner spike → dinner ICR or portion size
  • Late correction boluses → risk of overnight stacking; counsel on active insulin time
  • Nocturnal lows (11PM–5AM) → review evening correction bolus doses and overnight basal

STEP 4 — HYPOGLYCAEMIA ASSESSMENT

If time below 70 is ≥4% or any time below 54 is present — address this before anything else.

Identify timing:

  • Nocturnal (11PM–5AM) → overnight basal too high; counsel on evening bolus timing; in 780G, check if suspend-before-low is active
  • Post-meal (<3 hours after bolus) → food bolus too large; ICR needs adjusting; counsel on bolus timing with meals
  • Fasting / between meals → basal too high
  • Post-exercise → counsel on temp basal or reduced bolus before activity

CareLink Episode Summary hypo event types (if available):

EventAction
Basal Rate IncreaseReview basal settings, including temp basals
Rapid Falling Sensor RateCounsel patient to act on falling CGM arrows
Bolus with Falling Sensor RateReduce bolus when SG is already falling
Bolus Wizard Food BolusReview ICR and carb counting accuracy
Nocturnal Hypoglycaemia (11PM–5AM)Review overnight basal; counsel on evening boluses
Multiple Correction BolusesEducate on insulin stacking risk
Manual BolusEncourage Bolus Wizard use

780G Auto Mode: check suspend events

  • Suspend Before Low events → protective, expected ✓
  • Suspend on Low → actual hypoglycaemia reached; more aggressive prevention needed
  • Total suspend duration >2 hours/day → review overnight basal settings

STEP 5 — HYPERGLYCAEMIA ASSESSMENT

Identify dominant pattern — when does the glucose go high?

Fasting / overnight high:

  • Dawn phenomenon (3–7AM rise) → increase overnight basal rate or raise SmartGuard target for that period
  • Post-midnight high → insufficient evening correction or high-carb late meal

Postprandial highs (consistent meal period):

  • Breakfast high every day → breakfast ICR too low, or bolus given after eating
  • Lunch high → lunch ICR; check carb entry
  • Dinner high → dinner ICR; consider dual/square bolus for higher-fat meals

Site-change-related highs:

  • Glucose consistently rises 3–4 days after last set change → infusion site degrading; counsel on ≤3-day site rotation
  • Glucose improves after set change → site occlusion confirmed

Auto Correction clustering (780G):

  • Heavy Auto Correction at the same time each day → systematic meal bolus gap; adjust ICR for that period

CareLink Episode Summary hyperglycaemia event types (if available):

EventAction
Rising Sensor Rate Without BolusPatient missing meal boluses; counsel on pre-meal bolus
Delayed Site ChangeReinforce ≤3-day infusion site rotation
Basal Rate DecreaseReview basal settings
Dawn Phenomenon (3AM–7AM)Increase overnight basal or adjust SmartGuard target
Overcorrection of HypoglycaemiaCounsel on appropriate low treatment amounts
Pump Suspends >60 minAssess if suspend limits are set appropriately

STEP 6 — ADHERENCE & ENGAGEMENT FLAGS

Check these in the Adherence Report or Daily Review:

FlagThresholdAction
Sensor wear<5 days/week readingsCounsel on CGM wear benefits
BG readings (fingerstick)<4/dayDiscuss calibration/confirmation needs
Bolus Wizard use<67% of bolusesEncourage Bolus Wizard for all meals
Bolus override (negative)FrequentCounsel on following Bolus Wizard
Manual boluses (no Bolus Wizard)PresentEducate on Bolus Wizard accuracy
Infusion site interval>3.5 days averageCounsel on ≤3-day rotation
Basal/Bolus ratio skewedBasal >55%Likely under-bolusing for meals

OUTPUT FORMAT — CLINICAL SUMMARY

After working through Steps 1–6, present findings as:

Patient / Date Range:

GLYCAEMIC CONTROL SNAPSHOT

  • Overall TIR: X% (target ≥70%) — [Met / Not Met]
  • Time above range: X% — [Met / Not Met]
  • Time below range: X% — [Safe / Needs Attention]
  • Best day: [date, TIR%] | Worst day: [date, TIR%]

KEY FINDINGS

  1. [Most important pattern — e.g. "Consistent post-breakfast hyperglycaemia on all days"]
  2. [Second finding — e.g. "High Auto Correction (avg 38%) suggests meal boluses are underestimating carbs"]
  3. [Third finding — e.g. "No hypoglycaemia — lows <1%"]

PRIORITISED ACTION PLAN

  1. ✅ Safety first: [Address any hypoglycaemia]
  2. 🔧 Primary fix: [Biggest contributor to time out of range]
  3. 📋 Counselling: [Behavioural/adherence point]
  4. 🔄 Review in: [Timeframe — usually 2–4 weeks after any change]

CLINICAL GUARDRAILS

  • Never adjust more than one insulin setting per review cycle. Sequential changes allow attribution of effects.
  • In SmartGuard Auto Mode (780G): the system compensates for basal errors with auto corrections. A high auto correction % often points to meal bolus gaps rather than basal problems.
  • Set change timing matters: a glucose trace that is good days 1–2 after a set change but deteriorates by day 3–4 almost always points to infusion site degradation, not an insulin dose problem.
  • Sensor errors (interrupted traces, calibration flags) can produce spurious glucose readings — always cross-check sensor data with fingerstick BG if in doubt.
  • Day-to-day variability is normal. Look for patterns across ≥3 days before making any dose changes.
  • Do not interpret glucose excursions on sick days or travel days in isolation — contextual events explain transient outliers.
  • CGM does not replace clinical judgment. Download data supports decision-making but does not replace the full clinical picture (HbA1c, renal function, hypoglycaemia awareness, lifestyle context).

SOURCE

  • Medtronic CareLink™ Software Report Reference Guide (M995150AOU1_A, 2019)
  • Medtronic CareLink Pro Report Reference Guide
  • Petrovski G & Zivkovic M. "Five-step approach to interpreting Medtronic CareLink therapy management data." Journal of Diabetes Science and Technology, 2017. DOI: 10.1177/1932296817726553
  • International Consensus on Time in Range. Diabetes Care 2019;42:1593–1603

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL122026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する